BioCentury
ARTICLE | Clinical News

Galena plummets after halting NeuVax study

June 30, 2016 12:45 AM UTC

Galena Biopharma Inc. (NASDAQ:GALE) lost $1.68 (83%) to $0.35 on Wednesday after it said it will halt the Phase III PRESENT study of NeuVax nelipepimut-S at an independent DMC's recommendation based on an interim futility analysis.

The placebo-controlled, 758-patient study evaluated NeuVax plus the GM-CSF Leukine sargramostim to prevent recurrence of early stage, node-positive breast cancer, with a primary endpoint of disease-free survival. ...